Combined modality therapy for esophageal carcinoma: Preliminary results from a large Australasian multicenter study

Burmeister, Bryan; Denham, James W.; O'Brien, Maree; Jamieson, Glyn G.; Gill, P. Grantley; Devitt, Peter G.; Yeoh, Eric; Hamilton, C.S.; Ackland, Stephen P.; Lamb, David; Spry, Nigel; Joseph, David; Atkinson, Christopher D.; Walker, Quenten

doi:10.1016/0360-3016(94)00449-u

Cited by 49 publications

(33 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The INT 0123 study did not show an improvement of outcome by increasing the dose from 50.4 Gy to 64.8 Gy in a combined approach of RT and cisplatin/5-FU [18]. However, several other reports suggested an impact of the dose on outcome [2,14,22,24]. For definitive RCT, doses of at least 59.4 Gy are applied in many centers.…”

Section: Discussionmentioning

confidence: 99%

Radio(chemo)therapy Plus Resection Versus Radio(chemo)therapy Alone for the Treatment of Stage III Esophageal Cancer*

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Radio(chemo)therapy Plus Resection Versus Radio(chemo)therapy Alone for the Treatment of Stage III Esophageal Cancer*

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Although the 3-year survival rate of the 65 eligible patients was 37%, all five patients with T4 disease died within 18 months. In another large study from Australia, 79 patients with advanced-stage carcinoma, including 25 with systemic metastasis, were treated with 5-FU, CDDP, and 30 -35 Gy of radiation therapy (Burmeister et al, 1995). A 3-year survival rate of 9% was achieved in patients with advanced disease.…”

Section: Discussionmentioning

confidence: 99%

Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus

et al. 2003

View full text Add to dashboard Cite

We retrospectively investigated the efficacy and feasibility of concurrent chemoradiotherapy for patients with severe dysphagia caused by oesophageal squamous cell carcinoma. Concurrent chemoradiotherapy was performed in 57 patients with T3 or T4 disease containing M1 lymph node (LYM) disease. Chemotherapy consisted of protracted infusion of 5-fluorouracil (5-FU) 400 mg m À2 24 h À1 on days 1 -5 and 8 -12, combined with 2-h infusion of cisplatin (CDDP) 40 mg m À2 on days 1 and 8. Radiation treatment at a dose of 30 Gy in 15 fractions of the mediastinum was administered concomitantly with chemotherapy. A course schedule with 3-week treatment and a 1 to 2-week break was applied twice, with a total radiation dose of 60 Gy, followed by two or more courses of 5-FU and CDDP. In all, 24 patients (42%) achieved a complete response, and the 3-year survival rate was 19%. Major toxicities were leukocytopenia and oesophagitis, and there were two (4%) treatment-related deaths. In contrast, 22 patients with T3 disease survived longer than 35 patients with T4 disease (P ¼ 0.001); however, the survival rate in 15 patients with M1 LYM disease did not differ significantly from that in 42 patients without M1 LYM disease (P ¼ 0.3545). Our results indicate that definitive chemoradiotherapy is potentially curative for locally advanced oesophageal carcinoma with malignant stricture. The efficacy and survival of patients treated with this regimen are related to the T factor.

show abstract

“…Only 5% of patients failed to complete therapy and treatment-related mortality was 6%. In 79 patients treated with palliative chemoradiation for incurable esophageal cancer, Burmeister et al reported 3-year survival rates of 8.5% with durable palliation of dysphagia [12]. Radiation dose was 30Á35 Gy in 3 weeks and concurrent chemotherapy included a single dose of cisplatin (80 mg/m 2 ) followed by a continuous infusion of 5-FU at 800 mg/m 2 /day for 4 days.…”

Section: Discussionmentioning

confidence: 99%

Clinical benefit of palliative radiation therapy in advanced gastric cancer

et al. 2008

View full text Add to dashboard Cite

Combined modality therapy for esophageal carcinoma: Preliminary results from a large Australasian multicenter study

Cited by 49 publications

References 13 publications

Radio(chemo)therapy Plus Resection Versus Radio(chemo)therapy Alone for the Treatment of Stage III Esophageal Cancer*

Radio(chemo)therapy Plus Resection Versus Radio(chemo)therapy Alone for the Treatment of Stage III Esophageal Cancer*

Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus

Clinical benefit of palliative radiation therapy in advanced gastric cancer

Contact Info

Product

Resources

About